At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 90 enrolled
Drug / intervention
etanercept +2 moredrug
Likely dose
etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi Centre, Double Blind, Placebo-controlled Study to Evaluate the Non Steroidal Anti-inflamatory Drugs (NSAIDS) Sparing Effect of Etanercept in Adult Subjects With Axial Involvement of Spondyloarthritis
In Brief
A Phase 4 clinical trial evaluating etanercept and placebo for Axial Spondyloarthritis. Completed, enrolled 90 participants across 19 sites.
Detailed Summary
This study will compare the Non Steroidal Anti-Inflammatory Drugs (NSAIDs) sparing effect of etanercept with that of placebo in adult subjects with axial Spondyloarthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAxial Spondyloarthritis
CountriesFrance
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 2011
Enrollment StartMay 2011
Primary CompletionJan 2013
Study CompletionApr 2013
TodayJul 2026
First PostedFeb 17, 2011
Enrollment StartMay 1, 2011
Primary CompletionJan 1, 2013
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.4 years ago
Interventions
etanerceptdrug
etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
etanerceptdrug
etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
placebodrug
placebo subcutaneous (SC) injections once weekly for 8 weeks.